Drugs & Targets FDA Grants Accelerated Approval to Farydak For Patients with Multiple Myeloma March 31, 2015Vol.38 No.03
Provenge Immune Response Continued For Two Years in Phase II Study in BRPC March 31, 2015Vol.38 No.03
Phase III Trial of Imbruvica Unblinded Following Significant Increase in PFS March 31, 2015Vol.38 No.03
Drugs & Targets FDA Grants Accelerated Approval to Ibrance In HER2-Negative Metastatic Breast Cancer February 26, 2015Vol.38 No.02
TCGA Researchers Discover Genomic Differences in Cancers Caused by Infection February 26, 2015Vol.38 No.02
Study: Lymphoseek Patients Had Fewer Sentinel Lymph Nodes Removed Per Procedure February 26, 2015Vol.38 No.02
Cranial Irradiation Can Increase Risk of Pituitary Deficiencies Later in Life, Study Says February 26, 2015Vol.38 No.02
Imbruvica Demonstrates 88% Response Rate In Studies of Relapsed/Refractory CLL Patients February 26, 2015Vol.38 No.02
